Literature DB >> 29707340

Antiplatelet and anticoagulant for prevention of reocclusion in patients with atrial fibrillation undergoing endovascular treatment for low extremity ischemia.

Liangxi Yuan1, Cheng Chen2, Ziyuan Li2, Guanglang Zhu1, Junmin Bao1, Zhiqing Zhao1, Qingsheng Lu1, Zaiping Jing1.   

Abstract

BACKGROUND: The purpose of this study is to report the efficacy of the mono antiplatelet plus anticoagulation therapy for prevention of reocclusion in patients with atrial fibrillation (AF) undergoing endovascular treatment for lower extremity ischemia.
METHODS: From March 2014 to July 2016, 32 (21 males; range, 68-84 years) patients were submitted to endovascular therapy for low extremity ischemia with AF and all were treated with endovascular treatments to correct underlying lesions. Then 20 patients receive aspirin plus rivaroxaban post-operation and 12 patients receive aspirin plus warfarin to prevent reocclusion.
RESULTS: Complete reconstruction of occluded femopopliteal arteries with unimpeded blood flow to legs were successfully obtained in all 32 patients; 12 (37.5%) patients had acute ischemia, 17 (53.1%) patients had chronic ischemia, 3 (9.4%) patients had acute on chronic ischemia. Endovascular treatments including percutaneous transluminal angioplasty (PTA) and stenting were performed to correct residual lesions after the thrombolytic/thrombectomy procedure or to correct native lesions for chronic patients. All 32 patients showed significant improvements in symptoms and 4 patients improved completely. The mean ankle-brachial index (ABI) had risen from 0.43±0.21 preoperatively to 0.81±0.16 postoperatively (P<0.01), and the primary patency rates were 88.9% at 12 months, and 81.5% at 24 months. No episodes of major bleeding and only one patient showed positive fecal occult blood tests during the follow-up.
CONCLUSIONS: The mono antiplatelet plus anticoagulation therapy offers a safe and effective alternative for prevention of reocclusion in patients with AF undergoing endovascular treatment for lower extremity ischemic.

Entities:  

Keywords:  Atrial fibrillation (AF); anticoagulant; antiplatelet; endovascular therapy

Year:  2018        PMID: 29707340      PMCID: PMC5906330          DOI: 10.21037/jtd.2018.02.63

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  21 in total

Review 1.  New antithrombotic agents.

Authors:  J Hirsh; J I Weitz
Journal:  Lancet       Date:  1999-04-24       Impact factor: 79.321

2.  Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells.

Authors:  G P Gasic; C P Arenas; T B Gasic; G J Gasic
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo.

Authors:  Evren Caglayan; Marius Vantler; Olli Leppänen; Felix Gerhardt; Lenard Mustafov; Henrik Ten Freyhaus; Kai Kappert; Margarete Odenthal; Wolfram H Zimmermann; Michelle D Tallquist; Stephan Rosenkranz
Journal:  J Am Coll Cardiol       Date:  2011-06-21       Impact factor: 24.094

4.  Transbrachial and femoral artery approach endovascular therapy for flush infrarenal aortic occlusion.

Authors:  L Yuan; J Bao; Z Zhao; X Feng; Q Lu; Z Jing
Journal:  Eur J Vasc Endovasc Surg       Date:  2014-05-14       Impact factor: 7.069

5.  Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study.

Authors:  O Ahlehoff; G Gislason; M Lamberts; F Folke; J Lindhardsen; C T Larsen; C Torp-Pedersen; P R Hansen
Journal:  J Intern Med       Date:  2014-06-13       Impact factor: 8.989

Review 6.  Intertwining of thrombosis and inflammation in atherosclerosis.

Authors:  Kevin Croce; Peter Libby
Journal:  Curr Opin Hematol       Date:  2007-01       Impact factor: 3.284

7.  Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures.

Authors:  Stavros Spiliopoulos; Konstantinos Katsanos; Georgios Pastromas; Athanasios Diamantopoulos; Panagiotis Kitrou; Dimitris Siablis; Dimitris Karnabatidis
Journal:  Cardiovasc Intervent Radiol       Date:  2014-02-08       Impact factor: 2.740

8.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.

Authors:  C Michael Gibson; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W Verheugt; Peter Wildgoose; Mary Birmingham; Juliana Ianus; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Gregory Y H Lip; Marc Cohen; Steen Husted; Eric D Peterson; Keith A Fox
Journal:  N Engl J Med       Date:  2016-11-14       Impact factor: 91.245

9.  Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.

Authors:  Christian M Kinstner; Johannes Lammer; Andrea Willfort-Ehringer; Wolfgang Matzek; Michael Gschwandtner; Domagoj Javor; Martin Funovics; Maria Schoder; Renate Koppensteiner; Christian Loewe; Robin Ristl; Florian Wolf
Journal:  JACC Cardiovasc Interv       Date:  2016-07-11       Impact factor: 11.195

Review 10.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Authors:  Robert A Byrne; Michael Joner; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

View more
  1 in total

1.  Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization.

Authors:  Qingyuan Yu; Cheng Chen; Jinyan Xu; Yu Xiao; Junmin Bao; Liangxi Yuan
Journal:  Front Cardiovasc Med       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.